Trino Elisabetta, Mantovani Cristina, Badellino Serena, Ricardi Umberto, Filippi Andrea Riccardo
a Department of Oncology , University of Torino , Torino , Italy.
b Radiation Oncology , Città della Salute e della Scienza University Hospital , Torino , Italy.
Expert Rev Anticancer Ther. 2017 Apr;17(4):347-356. doi: 10.1080/14737140.2017.1296764. Epub 2017 Mar 1.
The clinical landscape of advanced melanoma drastically changed after the introduction of both targeted therapies and immunotherapy. This rapid development in systemic therapies led to a change in the management of patients with brain metastases, with the subsequent need to re-assess the role of local therapies, in particular stereotactic radiosurgery (SRS). Areas covered: In this non-systematic review, we report on the current knowledge on the use of SRS in combination with immunotherapy and BRAF/MEK inhibitors for patients with melanoma brain metastases, as well as ongoing trials in this field. Expert commentary: It is now more common to observe patients with melanoma brain metastases with better performance status and prolonged life expectancy. A combination of targeted therapy and immunotherapy, in different sequences, has been shown to be feasible and well tolerable, on the basis of retrospective reports. Additional data from ongoing prospective trials are however needed to confirm or not these findings and better explore the efficacy of the combination.
在引入靶向治疗和免疫治疗后，晚期黑色素瘤的临床格局发生了巨大变化。全身治疗的这一快速发展导致了脑转移患者管理方式的改变，随后需要重新评估局部治疗的作用，特别是立体定向放射外科（SRS）。涵盖领域：在本非系统性综述中，我们报告了目前关于SRS联合免疫治疗和BRAF/MEK抑制剂用于黑色素瘤脑转移患者的知识，以及该领域正在进行的试验。专家评论：目前更常见的是观察到黑色素瘤脑转移患者具有更好的身体状况和更长的预期寿命。根据回顾性报告，不同顺序的靶向治疗和免疫治疗联合已被证明是可行的且耐受性良好。然而，需要来自正在进行的前瞻性试验的更多数据来证实或否定这些发现，并更好地探索联合治疗的疗效。
